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Matrix metalloproteinases (MMPs) are a family of enzymes,
which take part in the regulation of the balance between synthesis
and breakdown of the extracellular matrix (ECM) (see Birkedal-
Hansen et al, 1993). Degradation of ECM is required both in
normal physiologic processes, as well as in pathologic tissue
remodelling occurring, e.g. in chronic wounds and in cancer.
MMPs seem to play an important role in different aspects of
tumour progression by enhancing tumour-induced angiogenesis
and breaking down ECM and basement membranes (BM) to allow
tumour growth and metastatic spread (Kähäri and Saarialho-Kere,
1999). 
Stromelysins-1 and -2 (MMPs-3 and -10) are structurally
closely related proteolytic enzymes that belong to the MMP gene
family. They are highly homologous in primary structure and
substrate specificity and they play a critical role in the activation of
procollagenases-1 (MMP-1), -2 (MMP-8) and -3 (MMP- 13)
(Nicholson et al, 1989; Knäuper et al 1996; Nagase, 1998).
Stromelysins-1 and -2 degrade in vitro e.g. collagen III and IV,
gelatin, casein, aggrecan, elastin, and proteoglycan core proteins
(Murphy et al, 1991; Chandler et al, 1997), while the activity of
MMP-10 on fibronectin is negligible compared to MMP-3
(Nagase, 1998). 
MMP-10 was initially identified in an adenocarcinoma cDNA
library (Muller et al, 1988), and since then its expression has been
associated with cancer invasion, mostly in tumours of epithelial
origin (Muller et al, 1991; Polette et al, 1991). It was later isolated
also from a rheumatoid synovial cell cDNA library and shown to
be differentially expressed from stromelysin-1 in human foreskin
and rheumatoid synovial fibroblasts (Sirum and Brinckerhoff,
1989). By Northern analysis, MMP-10 has been detected in
tumour cells at least in squamous cell carcinomas (SCCs) of the
head, neck and lung (Muller et al, 1991), and also in hepatocellular
carcinoma using immunoblotting (Lichtinghagen et al, 1995). No
MMP-10 expression has been found in colon, gastric or breast
adenocarcinomas, substantiating the epithelial origin of MMP-10
in vivo (McDonnell et al, 1991; Heppner et al, 1996). The exact
role of MMP-10 in tumour progression is not clearly understood.
However, MMP-10 has an important role in cutaneous and
intestinal wound healing. It is expressed at the wound edge by
migrating basal keratinocytes during both human and murine
wound repair (Saarialho-Kere et al, 1994; Madlener et al, 1996)
and by migrating enterocytes in inflammatory bowel disease
(Vaalamo et al, 1998). 
Overexpression of several MMPs correlates with the invasive
behaviour of tumour cells (Kähäri and Saarialho-Kere, 1999;
Werb, 1999). Expression of MMP-3 has been correlated with
tumour progression during skin carcinogenesis (Matrisian et al,
1991). Furthermore, overexpression of MMP-3 in transgenic mice
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Summary Co-expression of several members of the matrix metalloproteinase (MMP) family is characteristic of human malignant tumours. To
investigate the role of stromelysin-2 (MMP-10) in growth and invasion of skin tumours, we studied cutaneous carcinomas with high metastatic
capacity (squamous cell carcinomas, SCCs), only locally destructive tumours (basal cell carcinomas, BCCs) and pre-malignant lesions
(Bowen’s disease and actinic keratosis) using in situ hybridization. Expression of MMP-10 was compared with that of stromelysin-1 (MMP-3)
and of MT1-MMP, the expression of which has been shown to correlate with tumour invasiveness. MMP-10 was expressed in 13/21 SSCs
and 11/19 BCCs only in epithelial laminin-5 positive cancer cells, while premalignant lesions were entirely negative. MT1-MMP mRNA was
detected in 19/21 SCCs both in epithelial cancer cells and stromal fibroblasts and in 14/18 BCCs only in fibroblasts. The level of MMP-10 was
upregulated in a cutaneous SCC cell line (UT-SCC-7) by transforming growth factor-a and keratinocyte growth factor, and by interferon-g
in combination with transforming growth factor-b1 and tumour necrosis factor-a both in UT-SCC-7 and HaCaT cells. Our results show 
that MMP-10 expression does not correlate with the invasive behaviour of tumours as assessed by their histology and MT1-MMP expression,
but may be induced by the wound healing and inflammatory matrix remodelling events associated with skin tumours. © 2001 Cancer
Research Campaign http://www.bjcancer.com
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doi: 10.1054/ bjoc.2000.1634, available online at http://www.idealibrary.com on  http://www.bjcancer.comwas found to be sufficient to generate preneoplastic and malignant
mammary gland lesions (Sympson et al, 1995). We have previ-
ously demonstrated that MMP-3 and -13 are expressed by stromal
and cancer cells in cutaneous squamous cell carcinomas (SCC)
(Airola et al, 1997). However, MMP-3 was detected only in the
sclerosing subtype of basal cell carcinomas (BCC), which are non-
metastasizing, slow-growing but locally invasive and destructive
skin tumours. There is no data available on MMP-10 in premalign-
ant skin tumours or BCCs. 
MMPs are divided into 5 subgroups (collagenases, gelatinases,
stromelysins, membrane-type MMPs, and other MMPs) according
to their structure and substrate specificity. The first membrane-
type MMP (MT1-MMP) was detected on the surface of invasive
tumour cells in 1994 (Sato et al, 1994) and so far, altogether 6
distinct MT-MMPs have been found (Okada et al, 1995; Knäuper
and Murphy, 1998; Llano et al, 1999; Pei 1999). MT1-MMP is
believed to have an essential role in tumour cell invasion due to its
ability to activate latent gelatinase A. The expression of MT1-
MMP has been detected in tumour cells and adjacent stromal cells
in a variety of human cancers, including e.g. head and neck,
vulvar, lung, breast, colon, and liver carcinomas (Sato et al, 1994;
Okada et al, 1995; Harada et al, 1998; Johansson et al, 1999).
Expression of MT1-MMP is not found in normal epithelial cells,
but it is induced in transformed (Kadono et al, 1998) and in epithe-
lial carcinoma cells. High level of MT1-MMP expression has been
demonstrated to correlate with invasiveness both in vivo and in
vitro in several cancer types (Gilles et al, 1996; Pulyaeva et al,
1997; Mori et al, 1997). 
Although the expression of stromelysin-2 has been connected
with tumour invasion, its expression in human cancers in vivo is
poorly characterized. To investigate the role of stromelysin-2 in
skin cancers, we studied its expression in premalignant skin dis-
orders (Bowen’s disease and actinic keratosis), non-metastasizing
BCCs and in SCCs using in situ hybridization and Northern 
blot analysis. In this study, we show that MMP-10 mRNA is
already induced in BCCs, and co-localizes in epithelial cells with
laminin-5. There was no essential correlation with MMP-10 and
MT1-MMP expression in skin cancers, suggesting that MMP-10
expression may not necessarily be associated with higher invasive
capacity but with the presence of inflammation. The fact that
MT1-MMP is expressed in SCCs by cancer cells, but in BCCs
only by stromal fibroblasts, may contribute to less invasive
behaviour of BCCs as compared with that of SCCs. 
MATERIALS AND METHODS 
Tissue samples 
Formalin-fixed, paraffin-embedded specimens of SCC and BCC
were obtained from the Department of Dermatopathology,
University of Helsinki. The diagnoses were confirmed by 2 experi-
enced dermatopathologists. The following histologic specimens
were examined: squamous cell carcinomas (SCC): grades I (n = 9),
II (n = 7), III (n = 5), basal cell carcinomas (BCC) (n = 19) (histo-
logical subtypes: fibrosing (n = 11), keratotic (n = 3), adenoid 
(n = 5)), actinic keratoses (n = 6), and Bowen’s disease (n = 5). 
In situ hybridization 
A 175 bp fragment of human stromelysin-2 (corresponding 
to nucleotides 1568–1743) and a 217 bp fragment of human
stromelysin-1 were used to transcribe sense and anti-sense RNA
probes as described previously (Saarialho-Kere et al, 1994). A
1240-bp fragment of MT1-MMP cDNA (Lohi et al, 1996) was
subcloned to pGEM vector containing an SP6 RNA polymerase
recognition element. When linearized with BgI II, an antisense
RNA probe could be transcribed in vitro containing 405 bp from
3UTR of the MT1-MMP cDNA. The specificity of the probe was
confirmed by sequencing. As a control for nonspecific hybridiza-
tion, sections were hybridized with 35S-labelled sense RNA from
bovine tropoelastin cDNA. The validity of this probe as a negative
control has been confirmed by Northern (Prosser et al, 1989) and
by in situ hybridization (Saarialho-Kere et al, 1992). 
All sections were pre-treated with 1 mgm l –1 of proteinase K and
washed in 0.1 M triethanolamine containing 0.25% acetic acid.
Sections were hybridized with 35S-labelled probes (2.5–3 ´ 104
cpm ml–1 of hybridization buffer) at 50˚C for at least 18 hours in a
humidified chamber. Slides were then washed under stringent
conditions, including treatment with RNAse A to remove unhy-
bridized probe (Prosser et al, 1989). After 20–40 days of autoradi-
ography, the photographic emulsion was developed, and the slides
were stained with haematoxylin and eosin. Samples previously
positive for MMP-10 (chronic and acute wounds) were used as
positive controls. The slides were analysed independently by two
investigators (US-K, LJ). 
Immunohistochemistry 
Immunostaining was performed on sections parallel to those used
for in situ hybridization by the avidin-biotin-peroxidase complex
technique. Diaminobenzidine (DAB) was used as a chromogenic
substrate and haematoxylin as counterstain, as described in detail
(Saarialho-Kere et al, 1993). Sections were pre-treated with
trypsin (10 mg ml–1). Antibodies included polyclonal antibodies
against the c2-chain of laminin-5 (dilution 1:500, a kind gift from
Dr Karl Tryggvason, Karolinska Institut, Sweden), monoclonal
transforming growth factor-b1 (TGF-b1) (dilution 1:500,
MAB1032, Chemicon International, Temecula, CA), monoclonal
anti-MMP-2 (dilution 1:200, GE213, Diabor, Oulu, Finland), and
anti-human CD-68 (KP-1, dilution 1:300, M814; Dako,
Carpinteria, CA) for tissue macrophages. Controls were performed
with rabbit pre-immune serum or normal mouse immunoglobulin. 
Cytokines and growth factors 
Human recombinant tumour necrosis factor-a (TNF-a) and 
TGF-b1 were purchased from Sigma Chemical Co (St Louis,
MO). Human recombinant interferon-g (IFN-g) was obtained 
from Promega (Madison, WI). TGF-a, fibroblast growth factor-2 
(FGF-2, basic FGF) and keratinocyte growth factor (KGF) were
from Pepro Tech EC Ltd (Rocky Hill, NJ). 
Cell cultures 
UT-SCC-7 cell line was established from metastasis of a cutaneous
SCC at the time of operation in the Turku University Central
Hospital. Cell lines were cultured in DMEM supplemented with 
6 mM glutamine, non-essential amino acids and 10% fetal calf
serum (FCS). The SCC cells were examined in subcultures 5 to 10
and were homogeneous by visual inspection. HaCaT cells, an
immortalized human epidermal keratinocyte cell line, were kindly
provided by Dr Norbert Fusenig (DKFZ, Heidelberg, Germany).
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medium (DMEM) containing 10% FCS. 
RNA analysis 
Total cellular RNA was isolated from cell cultures using the single
step method (Chomczynski and Sacchi, 1987). Northern blot hybr-
idizations were performed as described previously (Johansson et al,
1997a) with cDNAs labelled with [a-32P]dCTP using random
priming. The 271-bp fragment of MMP-10 cDNA utilized for 
in situ hybridizations was also used for Northern blot hybridizations.
In addition, a 1.3 kb rat cDNA for glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (Fort et al, 1985) was used for hybridizations.
[32P]-cDNA/mRNA hybrids were visualized by autoradiography. 
RESULTS 
Expression of stromelysin-2 in SSC by cancer cells 
Stromelysin-2 was expressed in 13/21 SCC samples by epithelial
cancer cells (Figure 1A,B,b and 2A,E). It was generally more
abundantly expressed in tumours with a lot of inflammation, near
CD-68 positive inflammatory cells (Figure 1A,C). The tumours
found negative were typically devoid of inflammation or necrosis
(data not shown). There was no clear correlation between the
number of cells expressing stromelysin-2 and histological aggres-
siveness of the tumour (Table 1). However, highly differentiated
tumours tended to be negative or showed only a weak signal for
stromelysin-2 mRNA (Table 1). 
Expression of stromelysin-1 was also studied in a subset of SCC
samples (Table 1). Both stromal and tumour cells expressed
stromelysin-1 mRNA (Figure 2C) and in only 4/18 samples did it
co-localize with stromelysin-2 (Figures 2A,C). 
Stromelysin-2 is not as strongly expressed in BCC as
stromelysin-1 
Stromelysin-2 mRNA was expressed also in BCCs in 11 of 19
samples studied (Table 1). Of the positive tumours, 8 of 11 repres-
ented the fibrosing subtype, and in 6 of them mRNA was detected
in cancer cells, while in 2 others the expression was connected
with the ulceration (Figure 3A,B,G). In general, the expression
was not as abundant as in SCCs and was located near necrotic
areas at the tumour surface. Stromelysin-1 expression was in most
samples more abundant than that of stromelysin-2, and it was more
often expressed by stromal cells surrounding tumour islands 
than by cancer cells (Figure 3D,H,I,i; Table 1). All specimens 
of Bowen’s disease and actinic keratosis were negative for
stromelysin-2, the expression of which has not been found in
normal intact skin (Saarialho-Kere et al, 1994). No specific signal
was detected using the sense control probe (Figure 1D). 
MT1-MMP mRNA partly co-localizes with stromelysin-2
in SCC, but not in BCC 
Production of MT1-MMP was examined, firstly, since its expres-
sion in BCCs is poorly characterized and, secondly, since the
expression of MT1-MMP may correlate with the invasiveness of
the tumour samples under investigation (Gilles et al, 1996; Mori 
et al, 1997). MT1-MMP mRNA was expressed in 19 of 21 SCCs
studied and in 11 of them positive signal was detected in cancer
cells (Figure 4B,C,c). Otherwise MT1-MMP was abundantly
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Table 1 Results of MMP-10, MMP-3 and MMP-14 in situ hybridization in squamous cell carcinoma (SCC)
and basal cell carcinoma (BCC) 
Number of samples/signal strength 
Diagnosis Total MMP-10 MMP-3 MT1-MMP 
SCC grade I 9 6/– 3/– 1/– 
2/+ca 2/+ca,str 1/+ca 
1/++ca 1/++ca 5/+str 
1/++str 1/++str 
SCC grade II 7 1/– 2/+ca 1/– 
3/+ca 1/+str 1/+str 
3/++ca 1/++str 2/+ca,str 
1/++ca 
2/+++ca,str 
SCC grade III 5 1/– 1/+ca 2/+ca,str 
3/+ca 3/+str 2/++ca,str 
1/++ca 1/++str 
BCC fibrosing 11 3/– 2/+ca 1/+ca 
6/+ca 1/+str 5/+str 
2/+ulcer 1/++str 5/++str 
1/+++str 
BCC keratotic 3 1/–  3/+str 
2/+ca 
BCC adenoid 5 4/– 4/– 
1/+ca 
In situ hybridization signal for MMPs was evaluated using dark-field microscopy. Signal strength was
assessed as follows: –, no detectable specific signal; +, specific signal in few cells; ++, specific signal in
moderate number of cells; +++, specific signal in high number of cells. Cells expressing mRNA were identified
as cancer cells (ca) or stromal cells (str). In some BCC samples, the signal was detected only in the area of
ulceration (ulcer), not at all in cancer cells. expressed by stromal fibroblasts (Figure 4D,E). There was a
partial co-localization of stromelysin-2 and MT1-MMP signal in 
4 samples (Figure 4A,B), but usually stromelysin-2 and MT1-
MMP had distinct expression patterns. In general, MT1-MMP was
expressed deeper at invasive tumour islands (Figure 3A,C). 
MT1-MMP mRNA was detected more often than stromelysin-2
mRNA in BCCs. It was expressed in all fibrosing (11) and kera-
totic (3) BCC samples but not in adenoid BCCs. Unlike in SCCs,
cells expressing MT1-MMP were not cancer cells, but stromal
fibroblasts surrounding tumour islands (Figures 3C and 4F,G). 
Stromelysin-2 co-localizes with laminin-5 in epithelial
cells 
Since laminin-5 has been associated with the invasive capacity 
of several carcinomas (Pyke et al, 1995), immunosignal for
laminin-5 was examined in, altogether, 13 SCCs and 11 BCCs.
Stromelysin-2-positive cells showed intracellular staining for
laminin-5 both in the areas of ulceration as well as at the borders of
invasive tumour islands (Figure 2A,B,E,F). However, laminin-5
was clearly more abundantly expressed so that the edges of many
tumour islands deeper in the dermis were laminin-5 but not
stromelysin-2 positive. Gelatinase A, which is known to be able to
degrade laminin-5 in epithelial cells (Giannelli et al, 1999), was
not found in the same cells (n = 14 SCCs, n = 6 BCCs), but rather
in fibroblasts surrounding cancer islands (data not shown). 
Since MT1-MMP has recently been shown to degrade and co-
localize with laminin-5 at least in colon and breast cancer
(Koshikawa et al, 2000), we also compared its expression to
laminin-5 immunopositivity. We found, in altogether 13 SCCs and
11 BCCs, that MT1-MMP mRNA was not expressed in the same
cells as laminin-5, but rather in the stromal cells in the vicinity of
laminin-5 positive cancer cells (Figure 4D,E). 
Regulation of MMP-10 expression in SCC cells in
culture 
Previous studies have shown, that the expression of MMP-10 is
induced by phorbol ester, TGF-a and epidermal growth factor
(EGF) in normal epidermal keratinocytes (Windsor et al, 1993)
and by KGF, EGF, TNF-a and TGF-b1 in HaCaT keratinocytes
(Madlener et al, 1996). 43 cell lines established from primary and
recurrent tumours and metastases of SCCs of the head and neck at
the time of operation in the Turku University Central Hospital
(Johansson et al, 1997b) were examined for basal expression of
MMP-10. No basal MMP-10 mRNA expression was detected in
any of the cell lines derived from skin (n = 7), while 2 cell lines
from the larynx (n = 12) and 2 from the oral cavity (n = 22)
showed some basal expression (Figure 5A and data not shown). To
examine the regulation of MMP-10 expression in SCC cells by
Northern blot analysis, we chose the UT-SCC-7 a cell line,
because it was established from metastasis of a cutaneous SCC. In
this context, UT-SCC-7 cells were treated with TGF-a, FGF-2,
and KGF, all potent stimulators of keratinocyte proliferation.
Marked MMP-10 mRNA abundance was detected in UT-SCC-7
cells treated with TGF-a (10 ng ml–1) and KGF (10 ng
ml–1), whereas FGF-2 (10 ng ml–1) had no marked effect (Figure
5A). 
We have recently shown, that the expression of MMP-13 and
MMP-1 in SCC cells is potently inhibited by IFN-g (Ala-aho et al,
2000). Treatment of UT-SCC-7 cells with IFN-g (100 U ml–1)
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Figure 1 Expression of MMP-10 in SCCs. (A) In situ hybridization dark-field for MMP-10 mRNA in a grade II SCC depicting positive areas inside the tumour.
(B) A bright-field image of the same tumor. (b) A higher magnification of the MMP-10-positive cancer cells (arrows). (C) Immunostaining for CD-68 in a nearby
section. (D) In situ hybridization with the sense probe. Asterisks depict corresponding spots. Counterstaining was performed with haematoxylin and eosin in A,
B, D and with haematoxylin in C. Bars: 50 mm (A–D) and 12.5 mm (b) alone had no effect on MMP-10 mRNA levels, whereas treatment
with TGF-b1 (5 ng ml–1) and TNF-a (20 ng ml–1) slightly
enhanced MMP-10 mRNA expression (Figure 5B). Interestingly,
exposure of UT-SCC-7 cells to IFN-g in combination with TGF-b1
or TNF-a resulted in marked induction of MMP-10 expression
(Figure 5B). Abundant expression of MMP-10 mRNA was also
detected in HaCaT keratinocytes treated with TGF-b1, alone or in
combination with IFN-g (Figure 5C). In contrast to UT-SCC-7
cells, TNF-a alone or in combination with IFN-g had no marked
effect on MMP-10 expression. 
Based on our cell culture studies, immunoanalysis for TGF-b1
was performed in cancers. Generally stromelysin-2 positive cells
located in the vicinity of TGF-b1-positive areas (Figure 3E,F). 
DISCUSSION 
Stromelysin-2 has been thought to contribute to the invasive
behaviour of tumour cells. For example, transformed rat embryo
cell lines, which had elevated metastatic potential, produced high
amounts of both MMP-3 and MMP-10, while their expression was
not detected in nonmetastatic cell lines (Sreenath et al, 1992). To
date, however, only one report concerning positive MMP-10
expression in human cancers in vivo has been published. Using 
in situ hybridization, Polette et al (1991) detected MMP-3 and
MMP-10 expression in tumour cells arranged along disrupted
basement membranes and more often in stromal cells in close
contact to cancer cells in head and neck carcinoma. However, their
probe was a mixture of stromelysin-1 and -2. Furthermore, upreg-
ulation of MMP-10 was detected in human lung and head and neck
tumours by Northern analysis; abundant expression of both
stromelysin mRNAs, was associated with tumours showing more
probable local invasiveness (Muller et al, 1991). 
According to our present findings in vivo, despite marked
homology of MMP-3 and MMP-10, they still were expressed
differently. We found that both of them were upregulated in SCCs
and BCCs, but with very distinct patterns. MMP-10 was only
expressed by cancer cells in SCCs, which is in contrast with find-
ings on several other MMPs, that are mostly seen in cancer stroma
(Werb et al, 1999). The epithelial origin of MMP-10 is further
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Figure 2 Expression of MMP-10 and MMP-3 in SCCs. (A) In situ hybridization for MMP-10 in a grade I SCC. (B) Immunostaining for laminin-5 in a serial
section. (C) In situ hybridization showing MMP-3 mRNA in a nearby section. (D) Negative control for laminin-5 immunostaining. (E) Signal for MMP-10 mRNA
inside the tumour in a grade III SCC. (F) Positive staining for laminin-5 in a serial section. Arrows mark corresponding spots. Counterstaining was performed
with haematoxylin and eosin in A, C, E and with haematoxylin in B, D, F. Bar: 50 mm 664 E Kerkelä et al 
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Figure 3 Expression of MMP-10 and MMP-3 in BCCs. (A) In situ hybridization for MMP-10 mRNA in a fibrosing BCC showing expression in cancer cells. 
(B) Corresponding bright-field. (C) Signal for MT1-MMP mRNA in a serial section. (D) In situ hybridization for MMP-3 also in a serial section. (E)
Immunostaining for TGF-b1 in another fibrosing BCC. (F) MMP-10 mRNA in the same area in a nearby section. (G) Higher magnification of the same tumour as
in figure A depicting MMP-10 mRNA in epithelial areas. (H) Signal for MMP-3 mRNA showing entirely distinct expression pattern. (I) Corresponding bright-field
image. Arrows mark corresponding spots. (i) A closer view of the MMP-3 positive cells in the stroma (small arrows). Counterstaining was performed with
haematoxylin and eosin in A–D, F–I and with haematoxylin in E. Bars: 250 mm (A–D), 50 mm (E–I), 25 mm (i) substantiated by our novel results on Barrett’s adenocarcinomas in
which MMP-10 is only occasionally expressed in epithelial cells
in conjunction with ulceration (Salmela and Saarialho-Kere,
unpublished data). In BCCs, MMP-10 was also expressed in
cancer cells, except when the expression was connected with the
ulceration. In general, the expression was more sporadic than in
SCCs and located near necrotic areas at the tumour surface. MMP-
3 was more often expressed by stromal cells both in SCCs and
BCCs and was clearly more abundant than MMP-10 in BCCs
(Table 1). No signal for MMP-10 was detected in Bowen’s disease
or actinic keratoses, in agreement with data on MMP-3 (Tsukifuji
et al, 1999). Differential expression patterns of MMP-3 and -10
have also been demonstrated in developing human bone (Bord 
et al, 1998) and during cutaneous wound repair (Saarialho-Kere 
et al, 1994). It seems that they both have important, but still unique
roles in the degradation of ECM macromolecules in cancer. 
MMP-3 is considered to be an essential activator of various
proMMPs. Having a similar substrate specificity, also MMP-10 is
able to cleave several inactive proMMPs including MMPs-1, -7, 
-8, -9, and -13 (Karelina et al, 1994; Knäuper et al, 1996b;
Nakamura et al, 1998) of which at least MMP-9 and MMP-13 are
considered to be particularly important in the malignant behaviour
of the tumour cells. In skin cancers, MMP-10 could activate
MMP-9 or MMP-7 (Murphy et al, 1991). Pro-MMP-10 might be
activated by serine proteases known to be present in skin cancers
(see Nagase, 1998). 
Laminin-5, the main component of anchoring filaments, plays a
major part in keratinocyte adhesion and migration (Yancey, 1995).
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Figure 4 Expression of MT1-MMP in SCC and BCC. (A) A grade II SCC hybridized with MMP-10 antisense probe. (B) Signal for MT1-MMP in cancer cells in
the same area. (C) Corresponding bright-field. Arrows depict corresponding spots. (C) A higher magnification of the MT1-MMP positive cells (small arrows). 
(D) Signal for MT1-MMP mRNA in stromal cells in a grade III SCC. (E) Immunostaining for laminin-5 in a serial section. Arrows depict corresponding spots. 
(F) A fibrosing BCC island with MT1-MMP mRNA positive cells. (G) A closer view of positive fibroblasts (arrows). Counterstaining was performed with
haematoxylin and eosin in A–D, F–G and with haematoxylin in E. Bars: 50 mm (A–F), 25 mm (c) and 12.5 mm (G) MMP-10 in skin cancer 667
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Laminin-5 has been suggested to aid in the migration and invasion
of tumour cells by establishing focal adhesions to the matrix (Pyke
et al, 1995). According to Skyldberg et al (1999) g-chain of
laminin-5 co-localizes with the invasive cells in cervical lesions
and, thus, can serve as a marker for early invasion. In the samples
examined, MMP-10 mRNA was expressed by epithelial cells
producing laminin-5, implicating a migratory status of these cells.
However, laminin-5 was expressed more abundantly than MMP-
10, particularly deeper in the invasive borders of tumour islands.
Gelatinase A activity induces migration of breast epithelial cells
by cleaving and regulating the function of laminin-5 (Giannelli 
et al, 1999) and while this study was in progress, Koshikawa et al
(2000) showed that this also applies to MT1-MMP. In our own
SCC samples (n = 13), MT1-MMP and laminin-5 did not generally
co-localize in the same cells, but MT1-MMP mRNA located 
in stromal cells next to laminin-5 expressing cancer cells 
(Figure 4D,E). Thus, we cannot exclude that either MT1-MMP or
MMP-10 or both, might cleave laminin-5 during keratinocyte
motility in skin cancer. Instead, gelatinase A protein did not co-
localize with laminin-5 and apparently does not cleave laminin-5
during skin carcinogenesis. Interestingly, TGF-b1 is able to induce
both MMP-10 (Madlener et al, 1996) and laminin-5 in
keratinocytes (Kainulainen et al, 1998). 
Cultured human foreskin keratinocytes express MMP-10, while
fibroblasts express MMP-3. However, same agents, such as
phorbol esters, TNF-a, TGF-a, and EGF up-regulate the expres-
sion of both stromelysins (Windsor et al, 1993; Nagase, 1998).
The expression of MMP-10 is also induced by KGF and TGF-b1
in human transformed keratinocytes (HaCaT) (Madlener et al,
1996), that in some aspects mimic the phenotype of BCCs.
Interestingly, most of the SCC cell lines previously shown to be
producing MMP-1 and -13 basally (Johansson et al, 1997b), were
negative for MMP-10 mRNA. This suggests that malignant trans-
formation per se is not enough to induce MMP-10, but rather
inflammatory cytokines modify its expression. 
Phorbol ester stimulates the production of MMP-10 in certain
SCC cell lines, while IL-1b has no inducible effect (Nakamura 
et al, 1998). Tumour-infiltrating lymphocytes in SCCs express
IFN-g, which can inhibit proliferation of SCC cells (Kim et al,
1995; Arany et al, 1997) and stimulate production of MMP-1 and
MMP-3 by normal epidermal keratinocytes (Tamai et al, 1995).
Inflammatory cells may produce factors, eg. TNF-a and TGF-b1,
which can stimulate production of invasion-associated proteinases
by tumour and stromal cells. In our UT-SCC-7 cell line, TGF-a,
KGF and TGF-b1 clearly upregulated MMP-10. IFN-g in com-
bination with TGF-b1 and TNF-a resulted in marked induction of
MMP-10. Interestingly, the expression of 2 other MMPs relevant
in cancer biology, MMP-1 and -13 are also upregulated by the
same cytokines (Johansson et al, 1997b) but inhibited by IFN-g
(Ala-aho et al, 2000). The clinical picture of SCCs is characterized
by ulceration and inflammation of the lesions. Therefore, it is
possible that mediators of wound repair and inflammation, such as
TGF-b1, IFN-g, KGF, EGF and TNF-a, modulate invasion of
SCCs and thus MMP-10 upregulation can also be detected. In
agreement with that hypothesis, a positive immunostaining 
for TGF-b1 was seen in the same area as MMP-10 mRNA.
Furthermore, it has been shown, that high expression of IFN-g in
SCCs correlates with favourable prognosis (Arany et al, 1997).
This observation, in the context of our finding that IFN-g stimu-
lates SCC cell MMP-10 expression, suggests that MMP-10 is not
involved in the invasion of SCC cells. 
Membrane-associated MMPs (MT-MMPs) seem to have an
essential role in pericellular activation cascades of MMPs. MT1-
MMP at the cell surface, for example, may trigger invasion of
tumour cells by activation of pro-gelatinase A produced by stromal
cells (see Knäuper and Murphy, 1998). MT1-MMP mRNA has been
Control
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Figure 5 Enhancement of MMP-10 mRNA levels in SCC cells by TNF-a,
TGF-b1, TGF-a, and KGF. Cell line UT-SCC-7 established from a metastasis
of cutaneous SCC was incubated for 24 h in serum free medium (control), or
in the presence of (A) TGF-a (10 ng ml–1), FGF-2 (10 ng ml–1), or KGF 
(10 ng ml–1). (B) UT-SCC-7 cells and (C) HaCaT keratinocytes were treated
with IFN-g (100 U ml–1) for 1 h prior to adding TGF-b1 (5 ng ml–1) or TNF-a
(20 ng ml–1) for 24 h. Aliquots of total RNA (20 mg lane–1) were analysed by
Northern blot hybridization with cDNA probes specific for MMP-10 and
GAPDH. 28 S rRNA was visualized by ethidium bromide stainingdetected both in cancer and stromal cells (Okada et al, 1995;
Heppner et al, 1996; Ohtani et al, 1996; Harada et al, 1998). This
correlates with our results, since we found MT1-MMP mRNA
expression both in cancer cells and in stromal fibroblasts
surrounding SCCs. Ohtani et al (1996) suggested that the expression
of MT1-MMP in cancer cells might relate to invasive growth, while
in fibroblasts it may be implicated in tissue remodelling processes
caused by invasive cancer cells since it is able to digest types I and
III collagens, fibronectin, vitronectin, and proteoglycans (d’Ortho 
et al, 1997; Ohuchi et al, 1997). According to our results, MT1-
MMP-positive cancer cells were detected especially at the invasive
edge of tumour islands. Interestingly, MT1-MMP can activate latent
MMP-13 (Knäuper et al, 1996c) and based on our previous data
(Airola et al, 1997), may be serving this function at the epithelial
front. 
To our knowledge, this is the first report on MT1-MMP expres-
sion in BCCs. Unlike in SCCs, MT1-MMP expression was found
generally in stromal fibroblasts surrounding tumour islands. This
suggests that MT1-MMP produced by fibroblasts in BCC might
have another task than that produced by cancer cells in invasive
SCCs. The non-invasive nature of BCC supports this result.
Yoshizaki et al (1997) connected high levels of MT1-MMP
expression to highly differentiated head and neck SCCs.
According to our results, we found no significant difference in
intensity of MT1-MMP expression between poorly or well-
differentiated cutaneous tumours. 
In conclusion, this is the first study showing differential expres-
sion of stromelysin-1 and -2 in human cancer tissues in vivo.
Conversely to some previous in vitro reports, the present study
shows that stromelysin-2 expression does not correlate with the
invasive behaviour of tumours as assessed by their histology and
MT1-MMP expression, but may be induced by several cytokines
functioning in ulcerative phenomena and inflammatory matrix
remodelling associated with skin tumours. 
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